XTL Biopharmaceuticals Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.285 million compared to USD 1.15 million a year ago. Basic loss per share from continuing operations was USD 0.001 compared to USD 0.002 a year ago.
For the six months, net income was USD 0.221 million compared to net loss of USD 0.865 million a year ago.